Ilginatinib

N/A

Report date: 2025/04/22 20:00:06
NME

Base Information

Drug NameIlginatinib
Drug Alias NameIlginatinib - Nippon ShinyakuNS-018
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK2
Therapy Area/IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandThailand +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNippon Shinyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNs Pharma IncNippon Shinyaku Co Ltd
Active IndicationsN/A
Inactive IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera

Other Information

ATC CodeN/A
Related LinksN/A